Blueprint Medicines Co. (NASDAQ:BPMC) Director Sells $1,346,550.00 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $89.77, for a total transaction of $1,346,550.00. Following the completion of the sale, the director now directly owns 157,557 shares in the company, valued at $14,143,891.89. This represents a 8.69 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Blueprint Medicines Stock Performance

NASDAQ:BPMC traded up $1.21 during trading hours on Friday, reaching $90.14. 1,266,828 shares of the stock were exchanged, compared to its average volume of 690,804. Blueprint Medicines Co. has a 52 week low of $72.24 and a 52 week high of $121.90. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. The stock has a market capitalization of $5.73 billion, a P/E ratio of -42.72 and a beta of 0.59. The firm has a 50 day simple moving average of $92.45 and a 200-day simple moving average of $97.23.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The firm had revenue of $128.20 million during the quarter, compared to the consensus estimate of $127.56 million. During the same quarter in the previous year, the company posted ($2.20) earnings per share. The firm’s revenue was up 126.5% on a year-over-year basis. As a group, sell-side analysts forecast that Blueprint Medicines Co. will post -3.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on BPMC shares. StockNews.com upgraded shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday, November 8th. JMP Securities reissued a “market outperform” rating and set a $125.00 price target on shares of Blueprint Medicines in a research report on Monday, December 9th. UBS Group started coverage on Blueprint Medicines in a report on Thursday, October 24th. They issued a “neutral” rating and a $88.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and set a $135.00 target price on shares of Blueprint Medicines in a report on Friday, November 15th. Finally, Wells Fargo & Company cut their price target on shares of Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating on the stock in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $122.11.

Institutional Investors Weigh In On Blueprint Medicines

A number of hedge funds have recently made changes to their positions in the business. Amalgamated Bank increased its position in shares of Blueprint Medicines by 5.3% during the 2nd quarter. Amalgamated Bank now owns 2,154 shares of the biotechnology company’s stock valued at $232,000 after purchasing an additional 109 shares during the period. Van ECK Associates Corp lifted its stake in Blueprint Medicines by 13.3% during the second quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock valued at $120,000 after purchasing an additional 131 shares during the last quarter. EFG Asset Management North America Corp. lifted its holdings in shares of Blueprint Medicines by 0.5% during the second quarter. EFG Asset Management North America Corp. now owns 27,884 shares of the biotechnology company’s stock valued at $3,008,000 after purchasing an additional 132 shares during the last quarter. Pallas Capital Advisors LLC raised its holdings in Blueprint Medicines by 3.2% during the 3rd quarter. Pallas Capital Advisors LLC now owns 5,657 shares of the biotechnology company’s stock worth $523,000 after buying an additional 176 shares during the period. Finally, Clarus Wealth Advisors raised its stake in Blueprint Medicines by 8.6% during the 3rd quarter. Clarus Wealth Advisors now owns 2,590 shares of the biotechnology company’s stock valued at $231,000 after purchasing an additional 206 shares during the period.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.